Ischemia Reperfusion Injury - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463979 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Ischemia Reperfusion Injury - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 35 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ischemia Reperfusion Injury - Overview

Ischemia Reperfusion Injury - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ischemia Reperfusion Injury - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development

Akashi Therapeutics Inc

Argenx SE

Balmes Transplantation SAS

Bolder Biotechnology Inc

Catalyst Biosciences Inc

Celdara Medical LLC

Cellmid Ltd

CFM Pharma Holding BV

Corline Biomedical AB

Cypralis Ltd

Gilead Sciences Inc

Glucox Biotech AB

Ischemix Inc

Lee's Pharmaceutical Holdings Ltd

LG Chem Ltd

Mallinckrodt Plc

Orion Corp

Pfizer Inc

Radikal Therapeutics Inc

Reata Pharmaceuticals Inc

SBI Pharmaceuticals Co Ltd

Stealth BioTherapeutics Corp

United Therapeutics Corp

Ischemia Reperfusion Injury - Drug Profiles

aminolevulinic acid hydrochloride - Drug Profile

ANV-6L15 - Drug Profile

AP-39 - Drug Profile

APP-103 - Drug Profile

ARGX-117 - Drug Profile

AT-300 - Drug Profile

BBT-059 - Drug Profile

BT-0213 - Drug Profile

BT-0301 - Drug Profile

BT-0402 - Drug Profile

CAB-101 - Drug Profile

cannabidiol - Drug Profile

CB-2782 - Drug Profile

CC-4066 - Drug Profile

cerium oxide - Drug Profile

CMX-2043 - Drug Profile

cyclocreatine phosphate - Drug Profile

Cymac-001 - Drug Profile

DH-404 - Drug Profile

Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis - Drug Profile

IL-233 - Drug Profile

KN-93 - Drug Profile

LC-280126 - Drug Profile

MG-53 - Drug Profile

Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock - Drug Profile

Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile

MP-3964 - Drug Profile

NLS-3 - Drug Profile

NP-202 - Drug Profile

Oligonucleotide for Cardiovascular Diseases and Oncology - Drug Profile

ORM-10103 - Drug Profile

PEG-HCC - Drug Profile

Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile

R-100 - Drug Profile

R-190 - Drug Profile

Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders - Drug Profile

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile

Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile

Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile

Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile

regadenoson - Drug Profile

Remodulin - Drug Profile

Renaparin - Drug Profile

SBT-20 - Drug Profile

SBT-272 - Drug Profile

sirolimus - Drug Profile

Small Molecule to Agonize FPR1 and FPR2 for Ischemia Reperfusion Injury - Drug Profile

Small Molecules for Ischemia Reperfusion Injury - Drug Profile

Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation - Drug Profile

Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury - Drug Profile

Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile

Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile

Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury - Drug Profile

Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile

Synthetic Peptide for Ischemia Reperfusion Injury - Drug Profile

Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology - Drug Profile

Ti-061 - Drug Profile

tiomolibdate diammonium - Drug Profile

tiprelestat - Drug Profile

tofacitinib citrate - Drug Profile

UWA-TAT - Drug Profile

Vanadis-01 - Drug Profile

Vanadis-03 - Drug Profile

VCP-746 - Drug Profile

YQ-23 - Drug Profile

ZK-001 - Drug Profile

Ischemia Reperfusion Injury - Dormant Projects

Ischemia Reperfusion Injury - Discontinued Products

Ischemia Reperfusion Injury - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463979 | GMDHC11414IDB

Number of Pages

173

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
30-11-2017

$2,000 USD

Published by Global Markets Direct
31-10-2017

$2,000 USD

Published by Global Data
19-07-2017

$2,500 USD

Published by Global Markets Direct
11-07-2017

$2,000 USD

Published by Global Data
31-05-2017

$2,500 USD

Published by Global Markets Direct
23-05-2017

$2,000 USD

Published by Global Markets Direct
23-05-2017

$2,000 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Ischemia Reperfusion Injury - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.